Research programme: radionuclide oncology therapeutics - ITM Group
Latest Information Update: 28 Jul 2016
At a glance
- Originator itm Group
- Class Radioisotopes; Radiopharmaceuticals
- Mechanism of Action DNA modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Bone metastases; Neuroendocrine tumours; Prostate cancer; Skin cancer